Translation Services USA

ALL MARKETS
FTSE 100
FTSE 250
AIM MARKET


F. Hoffmann-La Roche Ltd.
45 announcements.
Time Ticker Company Announcement
06:00 0QQ6 F. Hoffmann-La Roche Ltd
FDA accepts Roche’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer
06:00 0QQ6 F. Hoffmann-La Roche Ltd
FDA grants priority review to Roche’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer
06:00 0QQ6 F. Hoffmann-La Roche Ltd
China National Medical Products Administration grants approval of Roche’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche provides topline results from investigator-led Phase II/III trial with gantenerumab in rare inherited form of Alzheimer’s disease
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche reports very strong results in 2019
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche’s Risdiplam meets primary endpoint in pivotal FIREFISH trial in infants with type 1 spinal muscular atrophy
06:00 0QQ6 F. Hoffmann-La Roche Ltd
European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche enters licensing agreement with Sarepta Therapeutics to improve the lives of patients living with Duchenne muscular dystrophy
06:00 0QQ6 F. Hoffmann-La Roche Ltd
European Commission approves Roche’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche purchases shares in tender offer for Spark Therapeutics, Inc.
07:23 0QQ6 F. Hoffmann-La Roche Ltd
Roche and Spark Therapeutics, Inc. announce unconditional clearance by UK Competition and Markets Authority
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche announces positive Phase III study results for Tecentriq plus Cotellic and Zelboraf in people with previously untreated BRAF V600 mutation-positive advanced melanoma
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche receives CE Mark for its Accu-Chek SugarView app
06:03 0QQ6 F. Hoffmann-La Roche Ltd
Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. to December 16, 2019
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Changes in the Board of Directors and the Corporate Executive Committee of Roche
06:00 0QQ6 F. Hoffmann-La Roche Ltd
FDA approves Roche’s Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Positive phase III results for Roche’s satralizumab in neuromyelitis optica spectrum disorder published in the New England Journal of Medicine
06:00 0QQ6 F. Hoffmann-La Roche Ltd
FDA grants priority review to Roche’s risdiplam for spinal muscular atrophy
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche to present new and updated data for seven approved and investigational medicines across multiple types of breast cancer at the 2019 San Antonio Breast Cancer Symposium
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche’s risdiplam meets primary endpoint in pivotal SUNFISH trial in people with type 2 or 3 spinal muscular atrophy
06:03 0QQ6 F. Hoffmann-La Roche Ltd
Roche’s Gazyva (obinutuzumab), in combination with standard of care, more than doubles the percentage of lupus nephritis patients achieving complete renal response, compared to standard of care alone
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche’s marketing applications for satralizumab in neuromyelitis optica spectrum disorder accepted for review by EMA and FDA
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche’s Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche announces FDA approval of Xofluza (baloxavir marboxil) for people at high risk of developing influenza-related complications
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche reports very strong sales growth in the first nine months of 2019 – outlook raised
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Phase III PEMPHIX study shows Roche’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress
06:00 0QQ6 F. Hoffmann-La Roche Ltd
FDA approves cobas Babesia, Roche’s first whole blood test for donor screening
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche renews its commitment to the primary healthcare Phelophepa trains, marking the 25th anniversary
06:00 0QQ6 F. Hoffmann-La Roche Ltd
FDA grants Breakthrough Therapy Designation for Roche’s Gazyva (obinutuzumab) in Lupus Nephritis
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche receives FDA clearance for cobas pro integrated solutions designed to help labs deliver faster results to patients
08:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche ranked as one of the most sustainable healthcare companies in the Dow Jones Sustainability Indices for the eleventh year running
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer
06:03 0QQ6 F. Hoffmann-La Roche Ltd
Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy
06:03 0QQ6 F. Hoffmann-La Roche Ltd
Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS
06:00 0QQ6 F. Hoffmann-La Roche Ltd
European Commission approves Roche’s new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer
06:03 0QQ6 F. Hoffmann-La Roche Ltd
European Commission approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer
06:00 0QQ6 F. Hoffmann-La Roche Ltd
Roche to present pivotal data for satralizumab in neuromyelitis optica spectrum disorder and six-year OCREVUS data in multiple sclerosis at ECTRIMS